Development
GSK plc
GSK
$41.30
$0.441.08%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 15.45% | 11.91% | 3.19% | -12.52% | -9.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.45% | 11.91% | 3.19% | -12.52% | -9.18% |
| Cost of Revenue | 10.80% | 8.95% | -11.81% | -35.82% | -15.20% |
| Gross Profit | 18.12% | 13.08% | 9.92% | 1.40% | -5.32% |
| SG&A Expenses | 14.10% | 18.11% | 14.76% | 5.19% | 3.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -313.90% | -31.58% | -457.81% | 83.09% | -58.03% |
| Total Operating Expenses | 4.65% | 13.73% | -2.17% | -12.70% | -6.10% |
| Operating Income | 93.68% | 8.13% | 19.54% | -12.00% | -26.57% |
| Income Before Tax | -75.35% | 90.32% | 120.90% | -17.60% | 367.57% |
| Income Tax Expenses | -2,109.48% | 18.62% | 60.70% | -22.68% | 100.74% |
| Earnings from Continuing Operations | -74.10% | 111.77% | 133.00% | -16.67% | 237.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -101.35% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 59.39% | -276.40% | -201.32% | 53.61% | -1,915.22% |
| Net Income | -75.24% | -85.45% | 93.04% | -25.18% | 73.91% |
| EBIT | 93.68% | 8.13% | 19.54% | -12.00% | -26.57% |
| EBITDA | 67.09% | -3.62% | -5.06% | -2.56% | -8.88% |
| EPS Basic | -75.37% | -85.54% | 91.74% | -25.69% | 72.88% |
| Normalized Basic EPS | 218.32% | 4.86% | 15.41% | 4.14% | -55.75% |
| EPS Diluted | -75.19% | -85.54% | 91.48% | -25.66% | 73.24% |
| Normalized Diluted EPS | 218.34% | 4.88% | 15.38% | 4.35% | -55.83% |
| Average Basic Shares Outstanding | 0.55% | 0.62% | 0.70% | 0.70% | 0.62% |
| Average Diluted Shares Outstanding | 0.61% | 0.59% | 0.71% | 0.47% | 0.74% |
| Dividend Per Share | 23.03% | 9.51% | -14.20% | -27.60% | -58.32% |
| Payout Ratio | 2.71% | 4.94% | -0.75% | -0.29% | -0.66% |